Skip to main content

Imaging

Artificial intelligence brings clarity to early bony changes in inflammatory arthritis

Jun 16, 2021

Subtle early bony changes in inflammatory arthritis can be hard even for experienced rheumatologists to interpret, even though they have traditionally been considered to become disease-defining as they progress. As computational techniques have become more sophisticated and more accessible,

Read Article
⭐️TORTUGA = PII trial that showed filgotinib (Jak1-i) signif improv SPARCC MRI scores (BM edema) in the spine + SIJ vs PBO in pts w/ active AS ⭐️OP0141 = post-hoc analysis that showed stat signif ⬇️ of CANDEN MRI scores (new bone format) w/ filgot at wk12 #EULAR2021 @Rheumnow https://t.co/RIpYIMcx1Q
Meral K. El Ramahi, MD @MeralElRamahiMD( View Tweet )
Jun 06, 2021
MSK US before 1st clinic visit? Abs#POS0260 showed ⬇️ in time to diagnosis of inflammatory arthritis from 31 to 12 days and ⬇️clinical visits 2.8 to 2.1 How do you use MSK US in your clinic? #EULAR2021 @RheumNow

Robert B Chao, MD @doctorRBC( View Tweet )

Jun 06, 2021
#EULAR2021 and EULAR IQ Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021. https://t.co/BkHjhOUqNU https://t.co/4JS1yGiJHg
Dr. John Cush @RheumNow( View Tweet )
Jun 05, 2021
HOT🔥: thermography of hands in IA remotely collected via smartphone correlates w/ US features 0.48, p<0.01 and SJC 0.48, p<0.01), DAS28 (0.73, p<0.01), CDAI (0.84, p<0.01) and SDAI (0.82, p<0.01). A future tool for patients remote follow-up? #OP0300 @Rheumnow #EULAR2021 https://t.co/MJLpz6eqIy
Aurelie Najm @AurelieRheumo( View Tweet )
Jun 04, 2021

RheumNow Podcast - EULAR 2021 & EULAR-IQ (6.4.21)

Jun 04, 2021

Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021.


Read Article
UPSTREAM results #OP0223 suggest that the newly developed and preliminary validated MSKUS PsA dz activity and damage scores could be used in observational and controlled trials. #EULAR2021 @RheumNow https://t.co/Tw7OWyMcgX https://t.co/WiT0yGwVqK
Dr. Rachel Tate @uptoTate( View Tweet )
Jun 04, 2021
Don’t forget to use imaging that you already have! CT Abd/Pelvis (ordered for nonMSK) of 301 IBD pts shows underlying sacroilitis ⭐️60/301 had sacroilitis on CT ⭐️11/60 had AxSpA ⭐️3/60 previously undiagnosed axSpA Abs#POS0035 #EULAR2021 @RheumNow

Robert B Chao, MD @doctorRBC( View Tweet )

Jun 03, 2021
Bingo. It always had been rather odd to me that you would call someone nr-SpA when they had MR evidence of disease; xrays are not sensitive to pick up changes. While we're at it, can we just use the term "imaging" instead of "radiographs" with the availability of better tech? https://t.co/I6reoHyywf
Jun 03, 2021
In biologic-naïve PsA pts - 2 yr data, GUS improved skin & joint symptoms, physical function, & radiographic progression. Safety comparable to 6mo/1yr data, similar between Q4W & Q8W dosing, & consistent w/ PsO trials. Poster #POS1027 #EULAR2021 @RheumNow https://t.co/nlcjOX7cBq https://t.co/NWqDTwfb4u
Dr. Rachel Tate @uptoTate( View Tweet )
Jun 03, 2021
So it comes down to the grand question: how on earth do we actually monitor disease activity?? "We still don't have a failsafe algorithm... relapse is both underdiagnosed & overdiagnosed" - @Sarah_L_Mackie The challenge lots of good people are working on! #EULAR2021 @RheumNow https://t.co/PUa6Ly1DQw
David Liew @drdavidliew( View Tweet )
Jun 03, 2021
#Eular2021: Do you start a bDMARD for nr-AxSpa without objective evidence of inflammation (elevated CRP, negative structural damage on MRI)? @RheumNow

Meral K. El Ramahi, MD @MeralElRamahiMD( View Tweet )

Jun 02, 2021
Some interesting abstracts at #EULAR2021 today on monitoring GCA with: - ultrasound OP0055 https://t.co/0fqLIK5IPV - PET/CT OP0069 https://t.co/WQl9VaHR9E OP0064 https://t.co/w7biFT6qy0 What do you believe is the most accurate measure of true disease activity in GCA? @RheumNow

David Liew @drdavidliew( View Tweet )

Jun 02, 2021

RheumNow Live 2021 Now Available for All

May 14, 2021

RheumNow Live (RNL) for 2021 was held March 20 - 21 in Fort Worth, TX, and now all can partake in the meeting - by video, podcast or by signing up for Tuesday Nite Rheumatology (TNR).



RNL has finished its 3rd year as a hybrid meeting, with the live meeting streamed to hundreds at home

Read Article

Risk Factors for Rheumatoid Arthritis-associated Interstitial Lung Disease

May 12, 2021

Sparks and colleagues have published a matched cohort analysis demonstrating risk factors that may augment the risk of rheumatoid arthritis (RA)-associated interstitial lung disease (ILD), especially the combination of obesity, high CRP, high MD-HAQ and >30 pack-year smoking history

Read Article

RheumNow Podcast – Uppers and Downers

Apr 30, 2021

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Read Article
Expansive differential diagnosis list of Spondyloarthritis/Sacroiliitis Mimics. Free read from Frontiers of Medicine; Early imaging is key to early diagnosis but may lead to misdiagnosis too. https://t.co/N3Vm0MxH9m https://t.co/hxBa065CMV
Dr. John Cush @RheumNow( View Tweet )
Apr 27, 2021

Golimumab Effective in non-radiographic Axial Spondyloarthritis

Apr 26, 2021

The GO-AHEAD study was designed to assess the long-term efficacy and safety of golimumab (GLM) in non-radiographic axial spondyloarthritis (nr-axSpA).  After the 16-week, placebo [PBO]-controlled double-blind phase, 189/198 (95.5%) entered the long-term extension (OLE) for 36 weeks wherein

Read Article

Diagnostic Delay in Spondyloarthritis

Apr 22, 2021

Literature review and metanalysis of many studies suggests that significant delay to diagnosis in axial spondyloarthritis (axSpA) exist, are longer than other rheumatic diseases and have not changed over time.



From a total of 64 studies identified the reported mean delay in diagnosing

Read Article

Increased Risk of COPD in ACPA+ Pre-RA Patients

Apr 21, 2021

The lung and its pathology is uniquely tied to rheumatoid arthritis (RA) and its pathogenesis.  A new study shows that elevation of anti–citrullinated protein antibodies (ACPAs) before diagnosis of RA increases the risk of developing chronic obstructive pulmonary disease (COPD) and/or asthma

Read Article
304 pts w/ Knee OA studied by MRI and atorvastatin 40 mg qd was no better than placebo in reducing cartilage volume loss, BM lesions, pain, or function over 2 years https://t.co/MIdIFQ9qzs

Dr. John Cush @RheumNow( View Tweet )

Apr 20, 2021

Broadalumab Efficacy in Axial Spondyloarthritis

Apr 19, 2021

Broadalumab (Siliq), an anti-interleukin-17 receptor A monoclonal antibody, is currently FDA- approved for use in adults with plaque psoriasis; but a recent trial shows it to be effective in patients with axial spondyloarthritis (axSpA).

Read Article

RheumNow Podcast – Combination Biologics

Apr 16, 2021

Dr. Jack Cush serves up this week's news and articles from RheumNow.com.

Read Article

IL-23 Targeting for Enthesitis in Psoriatic Arthritis

MedPage Today
Apr 13, 2021

Treatment with guselkumab (Tremfya) was effective in resolving enthesitis among patients with psoriatic arthritis (PsA), a post-hoc analysis of two phase III trials found.



At week 24, 45% of patients receiving subcutaneous guselkumab every 4 weeks and 50% of those given the medication

Read Article

Can Targeting RANKL in RA Heal Erosions?

MedPage Today
Apr 07, 2021

Treatment with denosumab (Prolia) helped heal bone erosions over 2 years among patients with rheumatoid arthritis whose disease activity was well controlled, researchers reported.

Read Article
×